On December 1, 2022, the Editorial Office of Cancer Drug Resistance (CDR) was very honored to interview Journal Editorial Board member Prof. Wafik S. El-Deiry, who is Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, Director of the Cancer Center at Brown University, and Director of the Joint Program in Cancer Biology at Brown University and Affiliated Hospitals, Providence, RI, USA.
In the interview, Prof. El-Deiry shared what motivated him to enter the field of oncology research, research advances, and challenges in the field. In addition, he shared that the original discovery of p21 is one of the most exciting things in his career. p21 was the first mammalian CDK inhibitor to be discovered, which eventually led to the discovery and development of a new class of now FDA approved CDK inhibitor drugs. Furthermore, he also gave some advice to young researchers. He stressed that young researchers should really consider pursuing oncology research when they do have some interest and skills on it. He said that they can really make a difference in the world. Finally, he talked about how cancer drug resistance is very important and has huge challenges, and hoped that we could continue making important progress.
View the complete interview at the link below: